Biocept (NASDAQ:BIOC) Trading Down 13.6%

Biocept Inc (NASDAQ:BIOC)’s share price fell 13.6% during trading on Thursday . The stock traded as low as $0.51 and last traded at $0.51, 1,732,798 shares traded hands during mid-day trading. A decline of 17% from the average session volume of 2,093,953 shares. The stock had previously closed at $0.59.

The stock has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.71 and a current ratio of 1.83.

Biocept (NASDAQ:BIOC) last released its quarterly earnings data on Wednesday, November 13th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. The company had revenue of $1.53 million during the quarter. Biocept had a negative return on equity of 268.76% and a negative net margin of 552.54%.

An institutional investor recently raised its position in Biocept stock. Vanguard Group Inc. boosted its stake in Biocept Inc (NASDAQ:BIOC) by 107.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,963 shares of the medical research company’s stock after purchasing an additional 80,756 shares during the period. Vanguard Group Inc. owned about 0.83% of Biocept worth $173,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.73% of the company’s stock.

About Biocept (NASDAQ:BIOC)

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Read More: Diversification in Your Portfolio

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.